Novo Nordisk A/S (NEO:NVON)
Canada · Delayed Price · Currency is CAD | Market Cap | 232.09B -55.9% |
| Revenue (ttm) | 66.62B +6.4% |
| Net Income | 22.08B +1.4% |
| EPS | 4.96 +1.8% |
| Shares Out | n/a |
| PE Ratio | 10.51 |
| Forward PE | 11.69 |
| Dividend | 0.15 (3.81%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 68,286 |
| Average Volume | 87,006 |
| Open | 4.110 |
| Previous Close | 4.160 |
| Day's Range | 4.010 - 4.110 |
| 52-Week Range | 3.780 - 9.030 |
| Beta | 0.40 |
| RSI | 34.49 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised...
FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths
Weight loss drug giant Novo Nordisk has received a warning letter from the U.S. Food and Drug Administration for failing to report side effects potentially linked to Ozempic usage, including two death...
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
2 Healthcare Stocks That Are Too Cheap to Ignore
Pfizer and Novo Nordisk are trading at (more than) reasonable levels given their underlying strengths. Both drugmakers could make pipeline progress that will allow them to improve their financial resu...
Novo Nordisk receives FDA warning regarding US inspection in 2025
Novo Nordisk said on Tuesday that it had received a warning letter from the United States Food and Drug Administration (FDA) regarding an inspection at the Danish drugmaker's site in Pl...
Novo Nordisk: Buying The Dip Before Volume Dominance
Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a shocking FY2026 guidance cut. Gross margin compressed as D&A and integration c...
Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen.
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock
Novo Nordisk is going to drastically reduce the price of its GLP-1 medications next year. The move could give the company's struggling growth rate a big boost.
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why
Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight...
HIMS Skyrockets on Reported Deal with NVO to Sell GLP-1s
Multiple reports state that Hims & Hers (HIMS) will partner with Novo Nordisk (NVO) to sell its GLP-1s through the telehealth company's platform. Marley Kayden covers the twists and turns of this tale...
Novo Nordisk drops Him & Hers lawsuit
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect to ...
Novo Nordisk drops Him & Hers lawsuit
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect to ...
Novo's Quiet Comeback Begins
Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability...
Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
"We have decided to drop the current court proceedings," Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back "if needed." It comes after an agreement between Novo...
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the Danish drugmaker said on Monday, ending a legal dispute that erupte...
Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars
Novo Nordisk has decided to sell its weight-loss drug through Hims & Hers' telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products.
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 9 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...
Hims shares jump after report of Novo Nordisk partnership that may end legal feud
Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans to sell its weight-loss drugs on the telehealth firm's platform, signaling a potential end to...
Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says.
Novo has agreed to sell its weight-loss drugs on Hims' platform, according to a report.
Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute
Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
Novo Nordisk is a top player in the weight loss market and has several more products on the way. Amgen's most advanced candidate in this space could earn approval in the coming years.
Can This Next-Gen Obesity Drug Save Novo Nordisk?
Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player.
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last mon...
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly's stronger GLP-1 growth and consistency support its premium versus Novo's conditional value...
Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies
U.S. considers global AI chip export restrictions, impacting Nvidia and AMD as shares fall on regulatory risk. A 30-day U.S. waiver allows India to purchase stranded Russian crude, aiming to stabilize...